Article | May 21, 2020

5 Key Considerations When Moving To Remote Monitoring In Our Ongoing Clinical Trials

Source: TransPerfect

By M. Christine Morris, Executive Director, Life Sciences Solutions, TransPerfect

laptop computer messaging

The COVID-19 pandemic has created obstacles for site monitoring in both ongoing and upcoming studies. This brave new world has inspired new recommendations by the FDA, EMA, and MHRA and led to an urgent push to explore and implement remote monitoring and oversight solutions. Sponsors need to know that activities are tracking toward successful trial conduct in accordance with the study protocol and other relevant regulations. They also need to ensure patient safety, with visibility into product/dosing administration and endpoint activities.

It is important to be able to catch and address any deviations from SOPs and protocols to remain compliant and mitigate any risks to patient safety, patient retention, data integrity, and regulatory inspection findings.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader